{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5","upperLimit":"27","value":"15"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"description":"Assessed in the crossover arm using the method of Kaplan Meier.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients on Arm 1 that progress after the start of course 2 and prior to completion of 12 courses receive 20 mg dexamethasone IV and high-dose (56 mg/m\\^2) carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for up to 12 additional courses in the absence of disease progression or unacceptable toxicity.\n\nCarfilzomib: Given IV Dexamethasone: Given IV Laboratory Biomarker Analysis: Correlative studies","id":"OG000","title":"Crossover Arm"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From date of crossover to date of death due to any cause, assessed up to 3 years from randomization","title":"Overall Survival Crossover Group","type":"SECONDARY","unitOfMeasure":"months"}